These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38735383)

  • 1. Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment.
    Jiang Y; Li S; Ramesh R
    Cancer Lett; 2024 Jun; 592():216932. PubMed ID: 38735383
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer.
    Sun BB; Wang GZ; Han SC; Yang FY; Guo H; Liu J; Liu YT; Zhou GB
    Cancer Lett; 2024 Jun; 592():216929. PubMed ID: 38697461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in small cell lung cancer: A new era?
    Capelletto E; Mariniello A; Novello S
    Lung Cancer; 2017 Jun; 108():252-253. PubMed ID: 28343730
    [No Abstract]   [Full Text] [Related]  

  • 4. ERCC1 and small cell lung cancer.
    Rossi G; Nannini N; Tiseo M
    J Thorac Oncol; 2010 Nov; 5(11):1876-7. PubMed ID: 20975385
    [No Abstract]   [Full Text] [Related]  

  • 5. Unravelling the biology of SCLC: implications for therapy.
    Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
    Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelioma and small cell lung cancer.
    Tsao AS; Heymach J
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1825-6. PubMed ID: 22005546
    [No Abstract]   [Full Text] [Related]  

  • 7. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
    Semenova EA; Nagel R; Berns A
    Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies for small cell lung cancer: Where do we stand?
    Arcaro A
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The molecular pathogenesis of small cell lung cancer].
    D'Angelo SP; Pietanza MC
    Zhongguo Fei Ai Za Zhi; 2010 Nov; 13(11):C46-57. PubMed ID: 21081036
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of NRF2 in Lung Cancer.
    Sánchez-Ortega M; Carrera AC; Garrido A
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Mak DWS; Li S; Minchom A
    Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Cancer: Management.
    Mott TF
    FP Essent; 2018 Jan; 464():27-30. PubMed ID: 29313655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.
    Cui J; Wang J; Shen Y; Lin D
    Genes Genomics; 2021 Feb; 43(2):105-114. PubMed ID: 33460027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of proliferation and apoptosis induced by a Na+/H+ exchanger-1 (NHE-1) antisense gene on drug-resistant human small cell lung cancer cells.
    Li S; Bao P; Li Z; Ouyang H; Wu C; Qian G
    Oncol Rep; 2009 May; 21(5):1243-9. PubMed ID: 19360300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer.
    Zhou J; Li Z; Li J; Gao B; Song W
    Curr Mol Med; 2019; 19(3):157-163. PubMed ID: 30813876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.
    Xie X; Kerrigan JE; Minko T; Garbuzenko O; Lee KC; Scarborough A; Abali EE; Budak-Alpdogan T; Johnson-Farley N; Banerjee D; Scotto KW; Bertino JR
    Cancer Biol Ther; 2013 Aug; 14(8):742-51. PubMed ID: 23792570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.